Bank of America Merrill Lynch is out with its report today on Edwards Lifesciences EW, maintaining Neutral.
In a note to clients, Bank of America Merrill Lynch writes, "Over the next five-plus years, there is no other new product opportunity in medtech of a similar potential size as the transcatheter aortic valve implantation market, and EW is the only stand-alone
player. EW has this opportunity at a time when large-cap medtech is severely growth challenged and threatened by margin uncertainty given health care reform, but flush with cash. We believe TAVI will stand alongside coronary stents as a core technology in the catheterization lab of the future."
Shares of EW closed Thursday at $82.55, down 5.69% from Wednesday's close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst ColorAnalyst RatingsBank of America Merrill LynchHealth CareHealth Care Equipment
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in